Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors (OPAL BEYOND)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01882439
Recruitment Status : Completed
First Posted : June 20, 2013
Results First Posted : September 15, 2017
Last Update Posted : September 15, 2017
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:
To examine the safety and efficacy of tofacitinib in subjects with active psoriatic arthritis who have previously had an inadequate response to at least one TNF inhibitor either due to lack of efficacy or an adverse event.

Condition or disease Intervention/treatment Phase
Psoriatic Arthritis Drug: Tofacitinib Other: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 395 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Actual Study Start Date : August 2013
Actual Primary Completion Date : April 2016
Actual Study Completion Date : April 2016


Arm Intervention/treatment
Experimental: Treatment Sequence A
Tofacitinib 5 mg BID for 6 months
Drug: Tofacitinib
tablets, 5 mg BID x 6 months

Experimental: Treatment Sequence B
Tofacitinib 10 mg BID for 6 months
Drug: Tofacitinib
tablets, 10 mg BID x 6 months

Placebo Comparator: Treatment Sequence C
Placebo for 3 months then tofacitinib 5 mg BID for 3 months
Other: Placebo
tablets, to match tofacitinib 5 mg BID x 3 months

Drug: Tofacitinib
tablets, 5 mg BID x 3 months

Placebo Comparator: Treatment Sequence D
Placebo for 3 months then tofacitinib 10 mg BID for 3 months
Other: Placebo
tablets, to match tofacitinib 10 mg BID x 3 months

Drug: Tofacitinib
tablets, 10 mg BID x 3 months




Primary Outcome Measures :
  1. Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Month 3 [ Time Frame: Month 3 ]
    ACR20 was calculated as a ≥20% improvement from baseline in tender/painful and swollen joint counts and ≥20% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, Health Assessment Questionnaire - Disability Index (HAQ-DI), and C-reactive protein (CRP).

  2. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Month 3 [ Time Frame: Month 3 ]
    The HAQ-DI assesses the difficulty a patient has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question, level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. Higher score indicates greater disability. Overall score was computed as the sum of the domain scores divided by the number of domains answered. The total possible score ranged from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Higher overall score indicates greater disability.


Secondary Outcome Measures :
  1. Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6 [ Time Frame: Week 2 and Months 1, 2, 3, 4, and 6 ]
    ACR50 was calculated as a ≥50% improvement from baseline in tender /painful and swollen joint counts and ≥50% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP. n=number of responders.

  2. Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6 [ Time Frame: Week 2 and Months 1, 2, 3, 4, and 6 ]
    ACR70 was calculated as a ≥70% improvement from baseline in tender /painful and swollen joint counts and ≥70% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP. n=number of responders.

  3. Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6 [ Time Frame: Week 2 and Months 1, 2, 4, and 6 ]
    ACR20 was calculated as a ≥20% improvement from baseline in tender /painful and swollen joint counts and ≥20% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP. n=number of responders.

  4. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6 [ Time Frame: Week 2 and Months 1, 2, 4, and 6 ]
    The HAQ-DI assesses the difficulty a patient has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question, level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. Higher score indicates greater disability. Overall score was computed as the sum of the domain scores divided by the number of domains answered. The total possible score ranged from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Higher overall score indicates greater disability. n=number of participants evaluable at each visit.

  5. Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components: C-reactive Protein (CRP) Levels: Month 3 [ Time Frame: Month 3 ]
    The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.

  6. Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Patient's Assessment of Arthritis Pain: Month 3 [ Time Frame: Month 3 ]
    Participants assessed the severity of their arthritis pain using a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain.

  7. Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Patient's Global Assessment of Arthritis: Month 3 [ Time Frame: Month 3 ]
    Participants answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The participant's response was recorded using a 100 mm VAS by placing a mark on the scale between 0 (very well) and 100 (very poorly).

  8. Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Physician's Global Assessment of Arthritis: Month 3 [ Time Frame: Month 3 ]
    The blinded investigator or qualified assessor assessed how the participant's overall arthritis appeared at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm VAS by placing a mark on the scale between 0 (very good) and 100 (very poor).

  9. Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Swollen Joint Count: Month 3 [ Time Frame: Month 3 ]
    Swollen joint counts are considered the most specific quantitative clinical measure used to assess the status of participants with inflammatory types of arthritis. Sixty six (66) joints were assessed by a blinded assessor to determine the number of joints that were considered swelling.

  10. Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Tender/Painful Joint Count: Month 3 [ Time Frame: Month 3 ]
    Tender/painful joint counts are considered the most specific quantitative clinical measure used to assess the status of participants with inflammatory types of arthritis. Sixty eight (68) joints were assessed by a blinded assessor to determine the number of joints that were considered tender or painful.

  11. Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6 [ Time Frame: Week 2, Months 1, 2, 3, 4, and 6 ]
    The PsARC covers 4 measures: Tender joint count, swollen joint count, the Physician's Global Assessment of Arthritis, and the Patient's Global Assessment of Arthritis. The PsARC response is defined as improvement in 2 of 4 items, 1 of which must be joint pain or swelling, without worsening in any measure. Improvement criteria: ≥20% improvement in Physician's Global Assessment of Arthritis; ≥20% improvement in Patient's Global Assessment of Arthritis; ≥30% improvement in tender joint count; and ≥30% improvement in swollen joint count. n=number of responders.

  12. Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Response: Months 1, 3, and 6 [ Time Frame: Months 1, 3, and 6 ]
    The PGA-PsO is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are rated separately over the whole body according to a 5-point severity scale, scored as 0=none; 1, 2, 3, or 4=most severe. The severity rating scores are summed and the average taken; the total average is rounded to the nearest whole number score to determine the PGA-PsO score on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe). n=number of participants evaluable at each visit.

  13. Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response: Months 1, 3, and 6 [ Time Frame: Months 1, 3, and 6 ]
    PASI determines psoriasis severity based on lesion severity and percentage of body surface area (BSA) affected. Lesion severity is assessed for erythema, induration, and scaling evaluated separately for the head and neck, upper limbs, trunk, and lower limbs and then rated for each body area according to a 5 point scale: 0=no involvement; 1=slight; 2=moderate; 3=marked; 4=very marked. BSA involvement is the extent (%) of body area affected by psoriasis and is assigned a numerical score: 0=no involvement; 1=0% to 9%; 2=10% to 29%; 3=30% to 49%; 4=50% to 69%; 5=70% to 89%; 6=90% to 100%. In each area, the sum of the severity rating scores is multiplied by the score representing the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The sum of the numbers obtained for each of the 4 body areas is the PASI. PASI75 is defined as a 75% reduction from baseline in PASI. n=number of responders.

  14. Change From Baseline in Dactylitis Severity Score (DSS): Months 1, 3, and 6 [ Time Frame: Months 1, 3, and 6 ]
    Dactylitis is characterized by swelling of the entire finger or toe. The DSS is a function of finger circumference and tenderness, assessed and summed across all dactylitic digits. The severity of dactylitis is scored on a scale of 0-3, where 0=tenderness and 3=extreme tenderness in each digit of the hands and feet. The range of total dactylitis scores for a participant is 0-60. Higher score indicates greater degree of tenderness. n=number of participants evaluable at each visit.

  15. Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Months 1, 3, and 6 [ Time Frame: Months 1, 3, and 6 ]
    The SPARCC Enthesitis Index identifies the presence or absence of tenderness at 16 enthesial sites, including the bilateral Achilles tendons, plantar fascia insertion at the calcaneus, patellar tendon insertion at the base of the patella, quadriceps insertion into the superior border of the patella, supraspinatus insertion into the greater tuberosity of the humerus, and medial and lateral epicondyles. On examination, tenderness is recorded as present (1) or absent (0) for each of the 16 sites, with an overall total score ranging from 0 to 16. Higher score indicates a greater number of sites that are affected by enthesitis. n=number of participants evaluable at each visit.

  16. Change From Baseline in the Leeds Enthesitis Index (LEI): Months 1, 3, and 6 [ Time Frame: Months 1, 3, and 6 ]
    Enthesitis is inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assesses enthesitis in 6 sites. Tenderness is recorded as either present (1) or absent (0) for each of the 6 sites, for a total score of 0-6. Higher score indicates greater severity of enthesitis. n=number of participants evaluable at each visit.

  17. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Component Summary Score: Months 1, 3, 6 [ Time Frame: Months 1, 3, 6 ]
    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The health domains are aggregated into two summary scores known as the physical component summary (PCS) score and the mental component summary (MCS) score. Normalized domain scores, PCS and MCS scores are used in the analyses. The component and domain scores were scored using the United States (US) 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 and SF36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher PCS score represents better physical health status. n=number of participants evaluable at each visit.

  18. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Component Summary Score: Months 1, 3, 6 [ Time Frame: Months 1, 3, 6 ]
    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The health domains are aggregated into two summary scores known as the PCS score and the MCS score. Normalized domain scores, PCS and MCS scores are used in the analyses. The component and domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 and SF36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher MCS score represents better mental health status. n=number of participants evaluable at each visit.

  19. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Functioning Domain: Months 1, 3, 6 [ Time Frame: Months 1, 3, 6 ]
    SF-36v2 acute is a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, & mental health. The 10 items of the physical functioning scale represent levels & kinds of limitations between extremes of physical activities, including lifting & carrying groceries; climbing stairs; bending, kneeling, or stooping; walking moderate distances; self-care limitations. The physical functioning items capture the presence & extent of physical limitations using a 3-level response continuum. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 & SF36 health domain scales & component summary measures have means of 50 & standard deviations of 10. A higher physical functioning domain score represents better physical functioning. n=number of participants evaluable at each visit.

  20. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-physical Domain: Months 1, 3, 6 [ Time Frame: Months 1, 3, 6 ]
    SF-36v2 acute is a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, & mental health. The 4-item role-physical scale covers an array of physical health-related role limitations, including: a) limitations in the kind of work or other usual activities; b) reductions in the amount of time spent on work or other usual activities; c) difficulty performing work or other usual activities; & d) accomplishing less. Items in the role-physical scale are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 & SF36 health domain scales & component summary measures have means of 50 & standard deviations of 10. A higher role-physical domain score represents better role-physical functioning. n=number of participants evaluable at each visit.

  21. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Bodily Pain Domain: Months 1, 3, 6 [ Time Frame: Months 1, 3, 6 ]
    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The bodily pain scale comprises of 2 items pertaining to the intensity of bodily pain and extent of interference with normal work activities. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 & SF36 health domain scales & component summary measures have means of 50 & standard deviations of 10. A higher bodily pain domain score represents less bodily pain. n=number of participants evaluable at each visit.

  22. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): General Health Domain: Months 1, 3, 6 [ Time Frame: Months 1, 3, 6 ]
    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The general health scale consists of 5 items including a rating of health and 4 items addressing the respondent's view and expectations of his or her health. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 & SF36 health domain scales & component summary measures have means of 50 & standard deviations of 10. A higher general health domain score represents better general health perceptions. n=number of participants evaluable at each visit.

  23. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Vitality Domain: Months 1, 3, 6 [ Time Frame: Months 1, 3, 6 ]
    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 4-item measure of vitality captures a broad range of subjective evaluations of well-being from feelings of tiredness and being worn out to feeling full of energy all or most of the time. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 & SF36 health domain scales & component summary measures have means of 50 & standard deviations of 10. A higher vitality domain score represents better vitality. n=number of participants evaluable at each visit.

  24. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Social Functioning Domain: Months 1, 3, 6 [ Time Frame: Months 1, 3, 6 ]
    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 2-item social functioning scale assesses health-related effects on quantity and quality of social activities. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 & SF36 health domain scales & component summary measures have means of 50 & standard deviations of 10. A higher social functioning domain score represents better social functioning. n=number of participants evaluable at each visit.

  25. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-emotional Domain: Months 1, 3, 6 [ Time Frame: Months 1, 3, 6 ]
    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 3-item role-emotional scale assesses mental health-related role limitations in terms of a) time spent in work or other usual activities; b) amount of work or activities accomplished; c) care with which work or other activities were performed. All 3 items are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 & SF36 health domain scales & component summary measures have means of 50 & standard deviations of 10. A higher role-emotional domain score represents better role-emotional functioning. n=number of participants evaluable at each visit.

  26. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Health Domain: Months 1, 3, 6 [ Time Frame: Months 1, 3, 6 ]
    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 5-item mental health scale includes 1 or more items from each of 4 major mental health dimensions: anxiety, depression, loss of behavioral/emotional control, and psychological well-being. All items are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 & SF36 health domain scales & component summary measures have means of 50 & standard deviations of 10. A higher mental health domain score represents better mental health functioning. n=number of participants evaluable at each visit.

  27. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility: Months 1, 3, 6 [ Time Frame: Months 1, 3, 6 ]
    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.

  28. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-Care: Months 1, 3, 6 [ Time Frame: Months 1, 3, 6 ]
    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.

  29. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities: Months 1, 3, 6 [ Time Frame: Months 1, 3, 6 ]
    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.

  30. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort: Months 1, 3, 6 [ Time Frame: Months 1, 3, 6 ]
    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.

  31. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression: Months 1, 3, 6 [ Time Frame: Months 1, 3, 6 ]
    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.

  32. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today: Months 1, 3, 6 [ Time Frame: Months 1, 3, 6 ]
    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.

  33. Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score: Months 1, 3, 6 [ Time Frame: Months 1, 3, 6 ]
    FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better fatigue status. n=number of participants evaluable at each visit.

  34. Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score: Months 1, 3, 6 [ Time Frame: Months 1, 3, 6 ]
    FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better (less) fatigue experience. n=number of participants evaluable at each visit.

  35. Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score: Months 1, 3, 6 [ Time Frame: Months 1, 3, 6 ]
    FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better (less) fatigue impact on daily functioning. n=number of participants evaluable at each visit.

  36. Change From Baseline in Score Evaluating Spondylitis Using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Months 1, 3, 6 [ Time Frame: Months 1, 3, 6 ]
    BASDAI is a validated self-assessment tool used to determine disease activity in participants with ankylosing spondylitis. Utilizing a VAS of 0-10 (0=none and 10=very severe) participants answered 6 questions measuring discomfort, pain, and fatigue. The final BASDAI score averaged the individual assessments for a final score ranging 0-10cm, with higher scores representing more severe ankylosing spondylitis disease activity. n=number of participants evaluable at each visit.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Active arthritis at screening/baseline as indicated by >/= 3 tender/painful and 3 swollen joints
  • Active plaque psoriasis at screening
  • Inadequate efficacy or lack of toleration to previously administered TNF inhibitor

Exclusion Criteria:

  • Non-plaque forms of psoriasis (with exception of nail psoriasis)
  • History of autoimmune rheumatic disease other than PsA; also prior history of or current, rheumatic inflammatory disease other than PsA

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01882439


  Hide Study Locations
Locations
Layout table for location information
United States, Alabama
Rheumatology Associates P.C.
Birmingham, Alabama, United States, 35205
Rheumatology Associates of North Alabama, PC
Huntsville, Alabama, United States, 35801-4414
United States, Arizona
Arizona Arthritis & Rheumatology Associates, P.C.
Glendale, Arizona, United States, 85306
United States, California
Medvin Clinical Research
Covina, California, United States, 91723
St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare
Fullerton, California, United States, 92835
Ronald Reagan UCLA Medical Center, Drug Information Center
Los Angeles, California, United States, 90095
UCLA David Geffen School of Medicine
Los Angeles, California, United States, 90095
San Diego Arthritis Medical Clinic
San Diego, California, United States, 92108
Stanford Hospital and Clinics
Stanford, California, United States, 94305
United States, Connecticut
New England Research Associates, LLC
Trumbull, Connecticut, United States, 06611
United States, Florida
Rheumatology Associates of Central Florida, PA
Orlando, Florida, United States, 32806
Millennium Research
Ormond Beach, Florida, United States, 32174
Arthritis Center, Inc.
Palm Harbor, Florida, United States, 34684
Integral Rheumatology & Immunology Specialists (IRIS)
Plantation, Florida, United States, 33324
Florida Medical Clinic, P.A.
Zephyrhills, Florida, United States, 33542
United States, Idaho
St. Luke's Clinic - Rheumatology
Boise, Idaho, United States, 83702
St. Luke's Intermountain Research Center
Boise, Idaho, United States, 83702
United States, Kentucky
Bluegrass Community Research, Inc
Lexington, Kentucky, United States, 40504
United States, Maryland
Klein & Associates, M.D., P.A.
Hagerstown, Maryland, United States, 21740
The Center For Rheumatology And Bone Research
Wheaton, Maryland, United States, 20902
United States, Massachusetts
Brigham & Women's Hospital
Boston, Massachusetts, United States, 02115
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Clinical Pharmacology Study Group
Worcester, Massachusetts, United States, 01605
United States, Minnesota
St. Paul Rheumatology, PA
Eagan, Minnesota, United States, 55121
United States, Missouri
Clayton Medical Research
Saint Louis, Missouri, United States, 63117
United States, Nebraska
Physician Research Collaboration, LLC
Lincoln, Nebraska, United States, 68516
United States, New Hampshire
Dartmouth-Hitchcock Medical Center (DHMC)
Lebanon, New Hampshire, United States, 03756
United States, Ohio
Cincinnati Rheumatic Disease Study Group, Inc.
Cincinnati, Ohio, United States, 45219
University Hospitals Case Medical Center
Cleveland, Ohio, United States, 44106
Paramount Medical Research & Consulting, LLC
Middleburg Heights, Ohio, United States, 44130
United States, Pennsylvania
East Penn Rheumatology Associates, PC
Bethlehem, Pennsylvania, United States, 18015
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States, 16635
United States, South Carolina
Low Country Rheumatology, PA
Charleston, South Carolina, United States, 29406
United States, Tennessee
Arthritis Clinic
Jackson, Tennessee, United States, 38305
West Tennessee Research Institute
Jackson, Tennessee, United States, 38305
United States, Texas
Adriana M. Pop-Moody, M.D., Clinic, P.A.
Corpus Christi, Texas, United States, 78404
Pioneer Research Solutions, Inc.
Cypress, Texas, United States, 77429
Metroplex Clinical Research Center
Dallas, Texas, United States, 75231
United States, Utah
Drug Shipment/Storage: Investigational Drug Services
Salt Lake City, Utah, United States, 84112
University of Utah Hospital & Clinics
Salt Lake City, Utah, United States, 84132
United States, Washington
Dynacare Laboratories
Seattle, Washington, United States, 98122
Seattle Rheumatology Associates
Seattle, Washington, United States, 98122
Swedish Medical Center
Seattle, Washington, United States, 98122
Australia, New South Wales
Royal Prince Alfred Hospital, Rheumatology Department
Camperdown, New South Wales, Australia, 2050
Australia, Queensland
Rheumatology Research Unit
Maroochydore, Queensland, Australia, 4558
Australia, Victoria
Emeritus Research Pty Ltd
Malvern East, Victoria, Australia, 3145
Belgium
Hospital Erasme - Clinique Universitaire de Bruxelles
Brussels, Belgium, 1070
ReumaClinic
Genk, Belgium, 3600
Universitair Ziekenhuis Gent
Gent, Belgium, 9000
University Hospital Leuven, Department of Rheumatology
Leuven, Belgium, 3000
ZNA Jan Palfijn
Merksem, Belgium, 2170
Brazil
CMIP: Centro Mineiro de Pesquisa Ltda /
Juiz de Fora, MG, Brazil, 36010-570
CETAC - DIAGNOSTICO POR IMAGEM (image only)
Curitiba, PR, Brazil, 80240-160
EDUMED - Educacao em Saude SS LTDA.
Curitiba, PR, Brazil, 80440-080
Hospital de Clinicas de Porto Alegre (HCPA) / UFRGS
Porto Alegre, RS, Brazil, 90035-003
Clinica Medica Bonfiglioli Ltda. / Clinica Bonfiglioli
Campinas, SP, Brazil, 13015-001
Radiologia Clínica de Campinas - RCC (Images only)
Campinas, São Paulo, Brazil, 13015-240
Czechia
Medical Plus s.r.o.
Uherske Hradiste, Czechia, 68601
France
Centre Hospitalier Sud-Francilien - Secretariat de Rhumatologie
Corbeil-Essonnes, Cedex, France, 91106
Hopital Avicenne
Bobigny, France, 93000
Germany
Rheumazentrum Prof. Dr. med Gunther Neeck
Bad Doberan, Germany, 18209
Charite Universitatsmedizin Berlin - Campus Charite Mitte
Berlin, Germany, 10117
Rheumapraxis Steglitz
Berlin, Germany, 12161
Schlosspark-Klinik
Berlin, Germany, 14059
Universitaetsklinikum Erlangen, Medizinische Klinik 3
Erlangen, Germany, 91054
CIRI - Centrum für innovative Diagnostik und Therapie Rheumatologie/Immunologie (GmbH)
Frankfurt am Main, Germany, 60528
Medizinische Universitatsklinik Freiburg
Freiburg, Germany, 79106
Universitaetsklinikum Des Saarlandes Und Medizinische Fakultaet Der Universitaet Des Saarlandes
Homburg, Germany, 66421
University Hospital of Cologne
Koeln, Germany, 50937
Elisabeth Klinik Bigge
Olsberg, Germany, 59939
Mexico
Hospital Angeles Clinica Londres
Mexico City, D.F, Mexico, 06700
Grupo Medico Camino S.C.
Mexico City, Distrito Federal, Mexico, 03310
CLIDITER, S.A. de C.V.
Mexico, Distrito Federal, Mexico, 06700
Universidad La Salle AC
Mexico, Distrito Federal, Mexico, 14000
Medica Sur, S.A.B. de C.V. (For Emergencies Only)
Mexico, Distrito Federal, Mexico, 14050
Centro Integral en Reumatologia SA de CV
Guadalajara, Jalisco, Mexico, 44160
Grupo Santa Bernardette S.A. de C.V.
Guadalajara, Jalisco, Mexico, 44200
Centro de Investigacion de Tratamientos Innovadores de Sinaloa, S.C
Culiacan, Sinaloa, Mexico, 80000
Sanatorio CEMSI Chapultepec (For Emergencies Only)
Culiacan, Sinaloa, Mexico, 80040
Hospital General de Culiacan "Dr. Bernardo J. Gastelum"
Culiacan, Sinaloa, Mexico, 80230
Star Medica S.A. de C.V. (For Emergencies Only)
Merdia, Yucatan, Mexico, 97133
Institute Medico Panamericano, S.A. de C.V. (For Emergencies Only)
Merida, Yucatan, Mexico, 97000
Unidad Reumatologica Las Americas SCP
Merida, Yucatan, Mexico, 97000
Centro de Investigacion Clinica Pensiones
Merida, Yucatan, Mexico, 97070
Centro Multidisciplinario para el Desarrollo
Merida, Yucatan, Mexico, 97130
Hospital Star Medica Merida (For Emergencies Only)
Merida, Yucatan, Mexico, 97133
Christus Muguerza del parque, S.A de C.V
Chihuahua, Mexico, 31000
Investigacion y Biomedicina de Chihuahua
Chihuahua, Mexico, 31000
Poland
Centrum Kliniczno-Badawcze J.Brzezicki, B.Gornikiewicz-Brzez
Elblag, Poland, 82-300
Centrum Radiologii for X-Ray only
Elblag, Poland, 82-300
NZOZ Centrum Reumatologiczne Indywidualna Specjalistyczna Praktyka Lekarska Lek. Med. Barbara Bazela
Elblag, Poland, 82-300
Wojewodzki Szpital Zespolony Zaklad Radiologii
Elblag, Poland, 82-300
Przychodnia Specjalistyczna Lekarskiej Spozielni Pracy "Medica" for X-Ray Only
Grodzisk Mazowiecki, Poland, 05-825
Specjalistyczne Gabinety Lekarskie "DERMED" Anna Kaszuba
Lodz, Poland, 90-265
NZOZ Lecznica MAK-MED S.C.
Nadarzyn, Poland, 05-830
Prywatna Praktyka Lekarska Prof. UM dr hab. Pawel Hrycaj
Poznan, Poland, 61-397
Reumatika Centrum Reumatologii nzoz
Warszawa, Poland, 02-691
Russian Federation
Regional State Budgetary Healthcare Institution of Karelia Republic "Republic Hospital n.a.
Petrozavodsk, Karelia Republic, Russian Federation, 185019
State Autonomic Healthcare Institution City Clinical Hospital # 7
Kazan, Republic of Tatarstan, Russia, Russian Federation, 420103
SBIH of Moscow "City Clinical Hospital#1 n. a. N.I. Pirogov" of the Healthcare Department of Moscow
Moscow, Russian Federation, 119049
City Neurological Centre "SibNeyroMed", LLC
Novosibirsk, Russian Federation, 630091
Limited Liability Company Consultative Diagnostic Rheumatology Center "Healthy Joints"
Novosibirsk, Russian Federation, 630099
State Budget Educational Institution of Highest Professional Education
Tomsk, Russian Federation, 634050
State Institution of Healthcare of Yaroslavl Region
Yaroslavl, Russian Federation, 150003
Slovakia
MEDMAN s.r.o. - reumatologicka ambulancia
Martin, Slovakia, 036 01
Spain
Hospital Clinico de Santiago
Santiago De Compostela, A Coruna, Spain, 15706
Corporacio Sanitaria Parc Tauli
Sabadell, Barcelona, Spain, 08208
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, Spain, 39008
Hospital Sierrallana
Torrelavega, Cantabria, Spain, 39300
Complejo Hospitalario Universitario A Coruna
A Coruna, Spain, 15006
Hospital Universitari Vall d'Hebron
Barcelona, Spain, 08035
Hospital Universitario Virgen Macarena
Sevilla, Spain, 41009
Hospital Universitaro Y Politecnico La Fe
Valencia, Spain, 46026
Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan Roc, Taiwan, 11217
Buddhist Dalin Tzu Chi General Hospital
Chia-Yi, Taiwan, 62247
Chang Gung Medical Foundation-Kaohsiung Branch
Kaohsiung City, Taiwan, 83301
Chung Shan Medical University Hospital
Taichung, Taiwan, 40201
China Medical University Hospital
Taichung, Taiwan, 40447
United Kingdom
Barking Havering and Redbridge University Hospitals NHS Trust
Goodmayes, Essex, United Kingdom, IG3 8YB
Barking, Havering and Redbridge University Hospitals NHS Trust
Romford, Essex, United Kingdom, RM7 0AG
The Dudley Group NHS Foundation Trust
Dudley, West Midlands, United Kingdom, DY1 2HQ
Bradford Royal Infirmary, BTHFT
Bradford, West Yorkeshire, United Kingdom, BD9 6RJ
Royal United Hospitals NHS Foundation Trust
Bath, United Kingdom, BA1 1RL
Bradford Teaching Hospitals NHS Foundation Trust
Bradford, United Kingdom, BD5 0NA
York Hospital, York Teaching Hospital NHS Foundation Trust
York, United Kingdom, YO31 8HE
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01882439     History of Changes
Other Study ID Numbers: A3921125
2013-001368-46 ( EudraCT Number )
First Posted: June 20, 2013    Key Record Dates
Results First Posted: September 15, 2017
Last Update Posted: September 15, 2017
Last Verified: September 2017
Keywords provided by Pfizer:
psoriatic arthritis
tofacitinib
ACR20
HAQ-DI
TNF inhibitor failure
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Psoriatic
Joint Diseases
Musculoskeletal Diseases
Spondylarthropathies
Spondylarthritis
Spondylitis
Spinal Diseases
Bone Diseases
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Tofacitinib
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action